91
Participants
Start Date
December 30, 2015
Primary Completion Date
February 23, 2021
Study Completion Date
February 23, 2021
PF-06755992
PF-06755992 will be administered on Day 1 of Cycles 1 and 2.
PF-06755990
PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
TDS-IM Electroporation Device
TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
Tremelimumab
PF-06753388 will be administered every 28 days.
PF-06801591
PF-06801591 will be administered every 28 days.
PF-06753512
Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab
Memorial Sloan-Kettering Cancer Center 53rd Street, New York
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan-Kettering Cancer Center, Sidney Kimmel Center, New York
Northwell Health, Lake Success
UPMC Hillman Cancer Center, Pittsburgh
National Institutes of Health Clinical Center, Bethesda
Duke University Medical Center, Durham
GU Research Network, Omaha
Banner-University Medical Center Tucson, Tucson
The University of Arizona Cancer Center-North Campus, Tucson
Comprehensive Cancer Centers of Nevada, Las Vegas
Seattle Cancer Care Alliance, Seattle
University of Washington Medical Center, Seattle
Smilow Cancer Hospital at Yale-New Haven, New Haven
Smilow Cancer Hospital Phase 1 Unit, New Haven
Garden State Urology, Morristown
Morristown Medical Center, Morristown
Garden State Urology, Rockaway
Garden State Urology, Whippany
Lead Sponsor
Pfizer
INDUSTRY